+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA CDMO Service Market by Service Type (Analytical Services, Formulation & Fill-Finish, Manufacturing Services), Application (Diagnostics, Therapeutics, Vaccines), End Users, Technology Platform, Scale - Global Forecast 2025-2030- Product Image
mRNA CDMO Service Market by Service Type (Analytical Services, Formulation & Fill-Finish, Manufacturing Services), Application (Diagnostics, Therapeutics, Vaccines), End Users, Technology Platform, Scale - Global Forecast 2025-2030- Product Image
New

mRNA CDMO Service Market by Service Type (Analytical Services, Formulation & Fill-Finish, Manufacturing Services), Application (Diagnostics, Therapeutics, Vaccines), End Users, Technology Platform, Scale - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6148453
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Pivotal Role of mRNA CDMOs in Accelerating Advanced Therapeutics from Early Research and Development through Commercialization Success

The rise of messenger RNA technology has fundamentally reshaped the biopharmaceutical development paradigm, driving unprecedented demand for specialized development and manufacturing partners. As the complexity of mRNA modalities continues to grow, organizational strategies have shifted toward collaborative models that leverage contract development and manufacturing organizations. These mRNA CDMOs now sit at the intersection of scientific innovation and production scalability, enabling biotechnology innovators and pharmaceutical leaders to access advanced capabilities without shouldering the capital burden of dedicated facilities.


In this context, the introduction of flexible CDMO partnerships has become a critical enabler for accelerating time-to-clinic and time-to-market for novel mRNA therapeutics and vaccines. By outsourcing analytical and formulation expertise, process optimization, manufacturing throughput, and quality oversight to experienced service providers, developers can navigate regulatory pathways more efficiently. This section unpacks the essential role that CDMOs play in transforming mRNA research breakthroughs into viable clinical candidates and commercial products, establishing them as indispensable allies for modern life sciences organizations.

Identifying the Key Technological and Regulatory Shifts Transforming the mRNA CDMO Landscape and Competitive Dynamics Globally

Over the past several years, key technological breakthroughs and policy reforms have converged to reshape the competitive landscape for mRNA CDMO services. Advanced lipid nanoparticle formulations and novel delivery platforms have expanded the range of indications, while digital bioprocessing solutions and continuous manufacturing have unlocked higher yields and reproducibility. Concurrently, regulatory agencies have introduced expedited review pathways and harmonized guidelines, facilitating faster transitions from preclinical validation to clinical testing.


These combined forces have not only increased capacity but also elevated industry standards, compelling CDMOs to invest in state-of-the-art facilities, automation, and data-driven quality management. As end users demand more tailored, scalable solutions, service providers must continuously innovate to remain competitive. This dynamic environment is driving new alliances between biotech innovators and contract partners, positioning mRNA CDMOs as strategic collaborators in a rapidly evolving life sciences ecosystem.

Assessing the Far-Reaching Consequences of New United States Tariff Policies on the Cost Structures and Supply Chains of mRNA CDMO Services

With the implementation of new tariff regulations on key raw materials and components in 2025, contract developers and manufacturers of mRNA therapeutics are encountering significant cost pressures that challenge traditional supply chain models. Tariffs applied to imported nucleotides, lipid nanoparticle constituents, and specialized reagents have escalated production expenses, compelling organizations to reassess their sourcing strategies. These policy changes have also prompted longer lead times as suppliers reconfigure their logistics networks and recalibrate inventory holdings to mitigate additional duties.


In response, many CDMOs are accelerating initiatives to localize critical manufacturing steps and engage in long-term procurement partnerships with domestic and near-shore suppliers. This strategic pivot not only aims to stabilize input costs but also enhances supply chain resilience against future trade volatility. By adopting a regionalized approach to raw material sourcing and adopting advanced forecasting tools, service providers can better insulate their operations from external economic headwinds while preserving the agility required to meet evolving client demands.

Deriving Actionable Insights from Comprehensive Segmentation of mRNA CDMO Services Spanning Service Types Applications End Users Technologies and Scales

A multifaceted segmentation framework offers deep insight into the nuanced service portfolios available within the mRNA CDMO market. When examining service type, analytical offerings encompass bioanalytical testing, physical chemical characterization, and stability studies, each critical for ensuring the integrity and performance of mRNA candidates. Formulation and fill-finish capabilities range from liquid formulation to lyophilized presentation, while manufacturing services address both commercial scale production and research and development batches. Meanwhile, process development lines span upstream and downstream operations, with quality control testing and regulatory affairs support ensuring compliance throughout the product life cycle.


Applications further differentiate the market, with diagnostic assays, therapeutic interventions, and vaccine programs driving diverse service requirements. Vaccine development itself branches into cancer and infectious disease segments; cancer vaccines divide into prophylactic and therapeutic categories, while infectious disease vaccines focus on COVID-19 and seasonal influenza targets. Each of these application areas imposes distinct regulatory and technical demands, guiding CDMOs to tailor their platforms for optimal performance.


End users range from biotechnology innovators and pharmaceutical giants to specialized contract research organizations and academic research institutes, all seeking flexible partnerships to scale their mRNA endeavors. Technology platforms play a pivotal role in service selection, covering cationic and ionizable lipid nanoparticles, polymer-based delivery systems, and various viral vector formats including AAV, adenovirus, and lentivirus. Finally, production scale-from small and pilot batches to clinical and full commercial operations-dictates infrastructure requirements and influences capacity planning. Understanding this layered segmentation is essential for CDMOs to align their capabilities with evolving market needs and client expectations.

Evaluating Regional Dynamics and Growth Drivers Shaping Transformational Demand for mRNA CDMO Services across the Americas Europe Middle East and Africa and Asia-Pacific

Regional market dynamics reveal distinct growth trajectories for mRNA CDMO services across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, the presence of established biotech hubs and robust venture capital ecosystems has driven significant investment in cutting-edge facilities, while favorable regulatory reforms accelerate clinical translation. Patient access initiatives and public-private partnerships further reinforce demand for localized development and manufacturing capacity.


Across Europe, the Middle East, and Africa, collaborative funding programs and strategic government initiatives are expanding infrastructure, particularly in Western Europe and select Middle Eastern innovation zones. Regulatory harmonization via pan-European frameworks and targeted investment in workforce development are streamlining market entry. Meanwhile, the Asia-Pacific region is experiencing rapid growth fueled by national biotech strategies in China, Japan, and Australia, supported by public incentives, emerging contract service providers, and expanding domestic R&D pipelines. This geographic diversification underscores the importance of location-specific strategies for service providers and end users alike.

Highlighting the Strategic Positioning and Innovative Capabilities of Leading mRNA CDMO Service Providers Driving Industry Growth and Competitive Advantage

Leading service providers have distinguished themselves through strategic mergers, capacity expansions, and platform integrations that cater to the full spectrum of mRNA development needs. Major global players have invested in modular, multi-product facilities, enabling rapid line changeovers and flexible production volumes. Organizations boasting vertically integrated analytical, formulation, and manufacturing suites are securing preferred partnerships by delivering consistent quality and streamlined timelines.


Innovation pipelines are further bolstered by targeted collaborations with technology licensors and academic centers, driving novel delivery modalities and process intensification. Companies that foster cross-functional expertise-combining process engineering, regulatory acumen, and digital operations-are setting new benchmarks for service excellence. This competitive landscape underscores the value of adaptive business models and continuous capacity enhancement as critical differentiators in an increasingly crowded CDMO market.

Outlining Practical Strategic Initiatives and Best Practices for Industry Leaders to Capitalize on Emerging Opportunities in the mRNA CDMO Landscape

To stay ahead in this evolving environment, industry leaders must prioritize investments in flexible manufacturing platforms and end-to-end digital integration. Embracing single-use systems, real-time analytics, and modular facility designs will enable rapid scale-up and efficient capacity utilization. Concurrently, strengthening supplier relationships for key raw materials, including lipid nanoparticle components and nucleic acid precursors, will mitigate supply chain risks exacerbated by evolving trade policies.


A concerted focus on regulatory intelligence is equally vital; proactive engagement with agencies and participation in standard-setting initiatives can accelerate approval pathways and reduce compliance burdens. Developing cross-sector alliances and consortium memberships will enhance knowledge exchange and drive collective innovation. Finally, cultivating specialized talent pools in process development, quality assurance, and automated manufacturing will position organizations to deliver differentiated offerings that meet the complex demands of the next wave of mRNA-based therapeutics and vaccines.

Exploring Rigorous Mixed Method Research Design Encompassing Data Collection Analysis and Validation to Ensure Robust mRNA CDMO Market Insights

The research approach combined thorough analysis of publicly available scientific literature regulatory filings and industry reports with primary interviews conducted among key stakeholders at leading contract service providers, biotechnology innovators, and regulatory authorities. Data triangulation ensured consistency and depth, enabling cross-verification across multiple information sources. Expert panel reviews provided critical validation of emerging trends and strategic priorities, particularly around technological advancements and policy shifts.


Quantitative insights and qualitative findings were integrated through rigorous data modeling and thematic analysis, revealing patterns in adoption rates, capacity expansion timelines, and segment-specific dynamics. Continuous validation cycles with subject matter experts ensured that the final conclusions reflect real-world operational considerations and future-oriented perspectives. This mixed-method design delivers a robust foundation upon which strategic decisions for mRNA CDMO engagement can be confidently based.

Delivering a Concise Synthesis of Critical Findings and Future Prospects in the Evolving mRNA CDMO Ecosystem for Informed Decision-Making

The confluence of scientific breakthroughs, regulatory acceleration, and strategic capacity investments has established mRNA CDMOs as pivotal partners in the biopharmaceutical value chain. Navigating new tariff landscapes while harnessing advanced delivery platforms requires agile operational models and proactive stakeholder collaboration. Regional variations underscore the need for location-specific approaches, while comprehensive segmentation highlights diverse service requirements across applications, end users, and production scales.


By synthesizing market dynamics, key company strategies, and actionable recommendations, this analysis offers a holistic perspective on the mRNA CDMO ecosystem. Organizations equipped with these insights can optimize their development pathways, de-risk supply chains, and capitalize on emerging growth opportunities. The evolving nature of mRNA technology ensures that continued innovation and adaptability will define long-term success in this competitive landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Service Type
    • Analytical Services
      • Bioanalytical Testing
      • Physical Chemical Characterization
      • Stability Studies
    • Formulation & Fill-Finish
      • Liquid Formulation
      • Lyophilized Formulation
    • Manufacturing Services
      • Commercial Manufacturing
      • Research And Development Manufacturing
    • Process Development
      • Downstream Process Development
      • Upstream Process Development
    • Quality Control & Assurance
      • Quality Control Testing
      • Regulatory Affairs Support
  • Application
    • Diagnostics
    • Therapeutics
    • Vaccines
      • Cancer Vaccines
        • Prophylactic Cancer Vaccines
        • Therapeutic Cancer Vaccines
      • Infectious Disease Vaccines
        • COVID-19 Vaccines
        • Influenza Vaccines
  • End Users
    • Biotechnology Companies
    • Contract Research Organizations
    • Pharmaceutical Companies
    • Research Institutes
  • Technology Platform
    • Lipid Nanoparticle
      • Cationic Lipid Nanoparticle
      • Ionizable Lipid Nanoparticle
    • Polymer-Based Systems
    • Viral Vector
      • AAV Vector
      • Adenovirus Vector
      • Lentivirus Vector
  • Scale
    • Clinical Scale
    • Commercial Scale
    • Pilot Scale
    • Small Scale

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan

This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Lonza Group Ltd
  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • FUJIFILM Diosynth Biotechnologies UK Limited
  • Boehringer Ingelheim International GmbH
  • Recipharm AB
  • AGC Biologics Inc.
  • Evonik Industries AG
  • WuXi Biologics (Cayman) Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing collaboration between mRNA CDMOs and biotechnology firms to optimize scalable production capacity
5.2. Advanced lipid nanoparticle delivery system customization driving differentiation among mRNA CDMO providers
5.3. Regulatory harmonization efforts in mRNA manufacturing processes to streamline global market approvals
5.4. Emergence of single-use bioreactor technologies enhancing flexibility and reducing contamination risk
5.5. Increasing investments in modular mRNA production facilities to support personalized medicine applications
5.6. Adoption of AI-driven process analytics and digital twins for real-time monitoring of mRNA synthesis quality
5.7. Expansion of CDMO service offerings to include end-to-end vaccine formulation and fill-finish solutions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA CDMO Service Market, by Service Type
8.1. Introduction
8.2. Analytical Services
8.2.1. Bioanalytical Testing
8.2.2. Physical Chemical Characterization
8.2.3. Stability Studies
8.3. Formulation & Fill-Finish
8.3.1. Liquid Formulation
8.3.2. Lyophilized Formulation
8.4. Manufacturing Services
8.4.1. Commercial Manufacturing
8.4.2. Research And Development Manufacturing
8.5. Process Development
8.5.1. Downstream Process Development
8.5.2. Upstream Process Development
8.6. Quality Control & Assurance
8.6.1. Quality Control Testing
8.6.2. Regulatory Affairs Support
9. mRNA CDMO Service Market, by Application
9.1. Introduction
9.2. Diagnostics
9.3. Therapeutics
9.4. Vaccines
9.4.1. Cancer Vaccines
9.4.1.1. Prophylactic Cancer Vaccines
9.4.1.2. Therapeutic Cancer Vaccines
9.4.2. Infectious Disease Vaccines
9.4.2.1. COVID-19 Vaccines
9.4.2.2. Influenza Vaccines
10. mRNA CDMO Service Market, by End Users
10.1. Introduction
10.2. Biotechnology Companies
10.3. Contract Research Organizations
10.4. Pharmaceutical Companies
10.5. Research Institutes
11. mRNA CDMO Service Market, by Technology Platform
11.1. Introduction
11.2. Lipid Nanoparticle
11.2.1. Cationic Lipid Nanoparticle
11.2.2. Ionizable Lipid Nanoparticle
11.3. Polymer-Based Systems
11.4. Viral Vector
11.4.1. AAV Vector
11.4.2. Adenovirus Vector
11.4.3. Lentivirus Vector
12. mRNA CDMO Service Market, by Scale
12.1. Introduction
12.2. Clinical Scale
12.3. Commercial Scale
12.4. Pilot Scale
12.5. Small Scale
13. Americas mRNA CDMO Service Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa mRNA CDMO Service Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific mRNA CDMO Service Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Lonza Group Ltd
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. Catalent, Inc.
16.3.4. Samsung Biologics Co., Ltd.
16.3.5. FUJIFILM Diosynth Biotechnologies UK Limited
16.3.6. Boehringer Ingelheim International GmbH
16.3.7. Recipharm AB
16.3.8. AGC Biologics Inc.
16.3.9. Evonik Industries AG
16.3.10. WuXi Biologics (Cayman) Inc.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. MRNA CDMO SERVICE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MRNA CDMO SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MRNA CDMO SERVICE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MRNA CDMO SERVICE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MRNA CDMO SERVICE MARKET: RESEARCHAI
FIGURE 26. MRNA CDMO SERVICE MARKET: RESEARCHSTATISTICS
FIGURE 27. MRNA CDMO SERVICE MARKET: RESEARCHCONTACTS
FIGURE 28. MRNA CDMO SERVICE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MRNA CDMO SERVICE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA CDMO SERVICE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MRNA CDMO SERVICE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PHYSICAL CHEMICAL CHARACTERIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PHYSICAL CHEMICAL CHARACTERIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY DOWNSTREAM PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY UPSTREAM PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CATIONIC LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CATIONIC LIPID NANOPARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY IONIZABLE LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY IONIZABLE LIPID NANOPARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY POLYMER-BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY POLYMER-BASED SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LENTIVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY LENTIVIRUS VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY PILOT SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MRNA CDMO SERVICE MARKET SIZE, BY SMALL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MRNA CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES MRNA CDMO SERVICE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 185. CANADA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 186. CANADA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 187. CANADA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 188. CANADA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 189. CANADA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 190. CANADA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 191. CANADA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 192. CANADA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 193. CANADA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 194. CANADA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 195. CANADA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 196. CANADA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 197. CANADA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. CANADA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. CANADA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 200. CANADA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 201. CANADA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 202. CANADA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 203. CANADA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 204. CANADA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 205. CANADA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 206. CANADA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 207. CANADA MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 208. CANADA MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 209. CANADA MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 210. CANADA MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 211. CANADA MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 212. CANADA MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 213. CANADA MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 214. CANADA MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 216. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 217. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 220. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 221. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 222. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 223. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 224. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 225. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 230. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 231. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 232. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 233. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 234. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 235. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 238. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 239. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 240. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 241. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 242. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 243. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 244. MEXICO MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA MRNA CDMO SERVICE MARKET SIZE, BY SCALE, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY FORMULATION & FILL-FINISH, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY QUALITY CONTROL & ASSURANCE, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2024 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2025-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA MRNA CDMO SERVICE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this mRNA CDMO Service Market report include:
  • Lonza Group Ltd
  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • FUJIFILM Diosynth Biotechnologies UK Limited
  • Boehringer Ingelheim International GmbH
  • Recipharm AB
  • AGC Biologics Inc.
  • Evonik Industries AG
  • WuXi Biologics (Cayman) Inc.

Related Topics

Related Reports

mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report - Product Image

mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report

  • Report
  • 166 Pages
  • Global
From
mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 183 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO - Global Strategic Business Report - Product Image

Nucleic Acid Therapeutics CDMO - Global Strategic Business Report

  • Report
  • 200 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Macromolecular CDMO Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Macromolecular CDMO Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.